Patents by Inventor Yaxian Cai

Yaxian Cai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11655248
    Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: May 23, 2023
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Yaxian Cai, Zhaobing Xu, Hailong Yang, Shiqi Han, Guoping Hu, Lihong Hu, Charles Z. Ding, Jian Li, Shuhui Chen
  • Publication number: 20230045991
    Abstract: A salt form and crystal form of a mutant IDHI inhibitor and a preparation method therefor.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 16, 2023
    Applicant: KPC PHARMACEUTICALS, INC.
    Inventors: Yaxian CAI, Bao YUE, Peng YU, Changqing WEI, Wenyuan QIAN
  • Patent number: 11453667
    Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: September 27, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Yaxian Cai, Zhaobing Xu, Hailong Yang, Shiqi Han, Guoping Hu, Lihong Hu, Charles Z. Ding, Jian Li, Shuhui Chen
  • Publication number: 20220281868
    Abstract: Macrocyclic derivatives, preparation methods therefor and pharmaceutical compositions comprising said derivatives, and uses thereof as therapeutic agents, especially as factor XIa inhibitors and in drugs for treating and preventing thromboembolisms and other diseases. Specifically disclosed is a compound represented by formula (I), and an isomer and pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 23, 2020
    Publication date: September 8, 2022
    Inventors: Yaxian CAI, Xiaobing YAN, Zhe CAI, Guoping HU, Charles Z. DING, Kevin X CHEN, Jian LI, Shuhui CHEN
  • Publication number: 20220204508
    Abstract: Disclosed are a class of macrocyclic derivatives, a preparation method therefor, a pharmaceutical composition containing the derivatives, and the use thereof as therapeutic agents, particularly as XIa factor inhibitors and in the preparation of a drug for treating and preventing thromboembolisms and other diseases. Particularly disclosed are compounds shown by formula (I), an isomer thereof and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 15, 2020
    Publication date: June 30, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Yaxian Cai, Xiaobing Yan, Ting Wang, Chengde Wu, Charles Z. Ding, Shuhui Chen
  • Publication number: 20210371411
    Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 18, 2019
    Publication date: December 2, 2021
    Inventors: Yaxian CAI, Zhaobing XU, Hailong YANG, Shiqi HAN, Guoping HU, Lihong HU, Charles Z. DING, Jian LI, Shuhui CHEN
  • Publication number: 20210147418
    Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 27, 2021
    Publication date: May 20, 2021
    Inventors: Yaxian CAI, Zhaobing XU, Hailong YANG, Shiqi HAN, Guoping HU, Lihong HU, Charles Z. DING, Jian LI, Shuhui CHEN
  • Publication number: 20150038490
    Abstract: The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: October 20, 2014
    Publication date: February 5, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kun Liu, Shawn J. Stachel, Craig A. Coburn, Thomas G. Steele, Richard Soll, Hao Wu, Xuanjin Peng, Yaxian Cai, Xiaoxiang Du, Jian Li
  • Patent number: 8865701
    Abstract: The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Grant
    Filed: February 20, 2010
    Date of Patent: October 21, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kun Liu, Shawn J. Stachel, Craig A. Coburn, Thomas G. Steele, Richard Soll, Hao Wu, Xuanjin Peng, Yaxian Cai, Xiaoxiang Du, Jian Li
  • Publication number: 20110306595
    Abstract: The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: February 20, 2010
    Publication date: December 15, 2011
    Inventors: Kun Liu, Shawn J. Stachel, Craig A. Coburn, Thomas G. Steele, Richard Soll, Hao Wu, Xuanjin Peng, Yaxian Cai, Xiaoxiang Du, Jian Li